Artificial pancreas

Main article: Diabetes mellitus

History

2023

An artificial pancreas has entered the market, to launch which you just need to enter your weight

On August 30, 2023, Beta Bionics announced the launch of the iLet Bionic Pancreas artificial pancreas. It is an autonomous insulin delivery system that simplifies the treatment of diabetes and reduces the burden on patients and doctors. The manufacturer raised $100 million to launch sales of the product in different regions of the world. Read more here.

Artificial pancreas technology has the potential to improve blood glucose control in children

On March 16, 2023, the results of a study on the effectiveness of the artificial pancreas, a closed-loop insulin delivery control system developed for young children with type 1 diabetes, were released.

The artificial pancreas constantly monitors blood glucose levels and automatically injects insulin through an insulin pump if necessary. This eliminates the need to perform regular glucose tests and eliminates the need for multiple injections throughout the day. This approach is especially important in the case of young patients who cannot tell about their well-being.

Artificial pancreas technology could significantly improve blood glucose control in children

The study involved 102 children aged 2 to 5 years. Of these, 68 received treatment through a closed-loop insulin delivery control system (the first group of patients), while another 34 (the second group) received standard care. Thus, the ratio of children in these two groups was 2:1. Data were collected over 13 weeks.

It turned out that artificial pancreas technology could significantly improve blood glucose control in children. Thus, in the study participants from the first group, the blood glucose level remained within the target range (from 70 to 180 mg per deciliter) for an average of three hours longer during the day than in patients from the second group. Moreover, the greatest difference was recorded at night - between 22:00 and 6:00, that is, at a time when maintaining glucose levels by traditional methods is the most problematic.

The study also examined the safety of the artificial pancreas. In particular, there were two cases of severe hypoglycemia in the closed-loop group and one case in the standard-of-care group. At the same time, in the group with an artificial pancreas, one case of diabetic ketoacidosis occurred due to a problem with the insulin pump tube.^[1]

Artificial pancreas created that has already helped dozens of diabetics

In mid-January 2023, scientists from the Institute of Metabolic Sciences at the University of Cambridge developed a fully automated closed-loop insulin delivery system that improved glucose control in adults with type 2 diabetes. The system does not increase attacks of low blood sugar compared to standard insulin therapy and does not require user involvement during meals. The results of an open-label, single-center, randomized crossover trial were published in the journal Nature Medicine. Read more here.

2022: A new artificial pancreas has been developed. She herself calculates insulin

In early April 2022, scientists presented an artificial pancreas. The tests carried out showed that the technology is more effective in managing diabetes than existing technologies. The device uses an algorithm to determine the amount of insulin to be injected and reads blood sugar levels to keep it stable.

Artificial pancreas developed

Treatment for type 1 diabetes can be challenging, especially in young children, due to fluctuations in levels of essential insulin and unpredictability about how much patients eat and exercise. Children are particularly at risk of dangerously low and high blood sugar levels, which can damage the body or even lead to. The death artificial pancreas, worn near the body and which constantly monitors blood glucose levels and automatically regulates insulin supply through, is pomp being trialled in 30 National Service (health care Great Britain NHS) diabetes centres by April 2023. About 875 people have already participated in the world's first nationwide study of this kind.

The technology allows you to refuse to take a finger sample to check blood sugar levels and prevent attacks of hypoglycemia and hyperglycemia. While most of the NHS's annual spending on diabetes, estimated at £10bn, goes towards treating type 2 diabetes, it is hoped the devices will help reduce costs by reducing the need for intervention in type 1 diabetes. Data collected from the technology experiment, along with other evidence, will be reviewed by the UK's National Institutes of Health and Quality of Care when considering a wider implementation of the device.^[2]

2021: Enlight Launch - Pancreatic 3D Printing Project

At the end of February 2021, the European Enlight project was launched, which is to develop a pancreatic model for testing drugs for diabetes. This model will be created using 3D printers made by Readily3D, using tomographic printing to create microstructures in less than 30 seconds. The research will be conducted at UMC Utrecht and EPFL academic centers, which in 2019 were the first to use bulk printing using specialized stem cells. UMC Utrecht is the initiator of this project. Read more here.

2017: Semiautomatic artificial pancreas created

As of June 2017, there are advanced devices, such as an artificial pancreas (a combination of an insulin pump and a continuous blood sugar monitoring system) that largely helps people with type 1 diabetes manage their condition and makes their lives easier. This device automatically checks blood sugar levels and releases the correct amount of insulin when needed. The device works in conjunction with a smartphone or tablet. As of 2017, there is only one type of artificial pancreas, and it is called the "hybrid system." It includes a sensor attached to the body to measure glucose levels every 5 minutes, as well as an insulin pump that automatically injects insulin through a pre-installed catheter.

Since the system is hybrid, it is not fully automated. This means that the patient must manually confirm the insulin doses administered. Therefore, in 2017, researchers are studying completely closed insulin delivery systems to ensure that the correct dose of the hormone is administered without the need for user intervention.

Notes